BCM
JUNO

Biomark Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Biomark Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,864,174
Closed -$85.2M – 3
2017
Q4 		$85.2M Hold
1,864,174
– – 94.86% 1
2017
Q3 		$83.6M Hold
1,864,174
– – 94.97% 1
2017
Q2 		$55.7M Sell
1,864,174
-304,427
-14% -$7.51M 91.25% 1
2017
Q1 		$48.1M Hold
2,168,601
– – 87.21% 1
2016
Q4 		$40.9M Hold
2,168,601
– – 84.62% 1
2016
Q3 		$65.1M Sell
2,168,601
-37,325
-2% -$1.16M 86.12% 1
2016
Q2 		$68.5M Buy
2,205,926
+603,364
+38% +$25M 87.91% 1
2016
Q1 		$61M Hold
1,602,562
– – 83.87% 1
2015
Q4 		$70.5M Buy
+1,602,562
New +$79.5M 85.76% 1

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Biomark Capital Management's JUNO Position: Q1 2018 in Review

Biomark Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,864,174 shares — an estimated $85.2M sold.

Biomark Capital Management first reported a position in JUNO in Q4 2015 and held it in 9 quarters. The position peaked at $85.2M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Biomark Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Biomark Capital Management sold 1,864,174 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $85.2M.
  • Biomark Capital Management first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 9 quarters.
  • Biomark Capital Management's Juno Therapeutics, Inc. position peaked at $85.2M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Biomark Capital Management's 13F filing for Q1 2018, filed 20 Apr 2018.